Penumbra, Inc. (PEN)
Stock Price Chart
Key Info
| Market Cap | 8.46B |
| Revenue (ttm) | 527.20M |
| Net Income (ttm) | 10.64M |
| Shares Out | 36.11M |
| EPS (ttm) | 0.30 |
| PE Ratio | 780.73 |
| Forward PE | 238.10 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 26, 2020 |
| Last Price | $234.22 |
| Previous Close | $236.00 |
| Change ($) | -1.78 |
| Change (%) | -0.75% |
| Day's Open | 234.43 |
| Day's Range | 232.15 - 237.30 |
| Day's Volume | 407,385 |
| 52-Week Range | 121.80 - 241.81 |
More Stats
| Market Cap | 8.46B |
| Enterprise Value | 8.26B |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 36.11M |
| Float | 33.76M |
| EPS (basic) | 0.30 |
| EPS (diluted) | 0.30 |
| FCF / Share | -0.95 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 0.13% |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 3.80M |
| Short Ratio | 8.52 |
| Short % of Float | 11.24% |
| Beta | 0.67 |
| PE Ratio | 780.73 |
| Forward PE | 238.10 |
| P/FCF Ratio | n/a |
| PS Ratio | 16.04 |
| PB Ratio | 13.64 |
| Revenue | 527.20M |
| Operating Income | 6.52M |
| Net Income | 10.64M |
| Free Cash Flow | -33.54M |
| Net Cash | 200.71M |
| Net Cash / Share | 5.56 |
| Gross Margin | 70.55% |
| Operating Margin | 1.24% |
| Profit Margin | 2.00% |
| FCF Margin | -6.36% |
| ROA | 0.82% |
| ROE | 1.54% |
| ROIC | 1.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 547 | 445 | 334 | 263 | 186 | 126 | 88.85 |
| Revenue Growth | 23.03% | 33.31% | 26.75% | 41.5% | 48.27% | 41.26% | - |
| Gross Profit | 372 | 293 | 217 | 171 | 124 | 82.84 | 57.88 |
| Operating Income | 47.51 | -0.85 | 1.17 | -1.35 | 4.18 | 3.01 | -1.13 |
| Net Income | 48.46 | 6.60 | 4.66 | 14.81 | 2.37 | -0.83 | 0.89 |
| Shares Outstanding | 34.75 | 34.14 | 32.98 | 30.46 | 11.99 | 4.61 | 4.30 |
| Earnings Per Share | 1.34 | 0.18 | 0.13 | 0.44 | 0.08 | -0.18 | 0.14 |
| EPS Growth | 644.44% | 38.46% | -70.45% | 450% | - | - | - |
| Operating Cash Flow | 26.65 | 28.81 | 12.69 | -12.81 | -20.69 | -6.39 | -3.40 |
| Capital Expenditures | -22.11 | -9.60 | -12.53 | -13.64 | -5.47 | -3.89 | -0.80 |
| Free Cash Flow | 4.54 | 19.21 | 0.16 | -26.44 | -26.16 | -10.28 | -4.19 |
| Cash & Equivalents | 189 | 201 | 215 | 129 | 149 | 51.54 | 13.68 |
| Total Debt | 82.30 | - | - | - | - | - | 6.00 |
| Net Cash / Debt | 107 | 201 | 215 | 129 | 149 | 51.54 | 7.68 |
| Assets | 666 | 515 | 477 | 308 | 264 | 121 | 71.15 |
| Liabilities | 180 | 92.59 | 76.26 | 41.71 | 31.33 | 22.28 | 22.99 |
| Book Value | 486 | 422 | 400 | 267 | 233 | -12.37 | -8.06 |
Company Profile
Company Details
| Full Name | Penumbra, Inc. |
| Country | United States |
| Employees | 2,700 |
| CEO | Adam Elsesser |
Stock Information
| Ticker Symbol | PEN |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NYSE: PEN |
| IPO Date | September 18, 2015 |
Description
Penumbra designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; rehabilitation tools that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.